Vaccibody AS   Report issue

For profit Phase 2
Founded: Oslo Norway (2007)

Organization Overview

First Clinical Trial
2015
NCT02529930
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Vaccibody AS

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma in Situ (Phase 2)

Cervical Intraepithelial Neoplasia (Phase 2)

Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 6